
NEWSLETTER ON GLOBAL CLINICAL TRIALS

Volume 3, November 2022

**Industry Insights for:
Biotech, Pharma, MedTech, Medical Device**



Our biweekly clinical trial newsletter can help you quickly identify new important trials and important conditions.

For more detailed information or more specific business intelligence analysis, please contact us at contact@buttontech.us

Powered by BUTTON Platform

2672 Bayshore Parkway, Suite 1001, Mountain View, CA 94043

WEB: <https://www.button-corp.com>

EMAIL: contact@buttontech.us

Table of Contents

1	SIGNIFICANT CLINICAL TRIALS BY DURATION	1
2	SIGNIFICANT CLINICAL TRIALS BY ENROLLMENT.....	2
3	CONTACT US FOR CUSTOMIZED BUSINESS INTELLIGENCE ANALYSIS.....	4

The big data platform built by BUTTON covers business intelligence, clinical data, regulatory information and supply chain data in Biotech/MedTech/Medical Device industry.

In this newsletter, we want to give you a glimpse of some features and insights about BUTTON's database on global clinical trials, which can be accessible in a more comprehensive manner on our platform. Herein, you can browse and get a quick understanding on the issues mentioned above – just as an iceberg, the most important dimensions are below the surface. If you get interested and want to grasp more details, information and data, please contact us at contact@buttontech.us.

1 Significant Clinical Trials by Duration


Generally speaking, a clinical trial with a longer duration may bring more business opportunities to other companies, such as CROs.

Table 1 shows **the expected durations of clinical trials** initiated between November 1st and 30th 2022, ranked in descending order. Figure 1 shows **the average expected durations by indications** for these clinical trials, ranked in descending order.

**Table 1: Significant Clinical Trials by Expected Durations
(Initiated between 11/01/2022-11/30/2022)**

Title	Phase	Indication	Start Date	Duration (years)
Long-term Follow-up of Patients \	Phase 3	Spinal Muscular Atrophy (SMA)	2022-11-16	16.9
A Study Evaluating the Efficacy a	Phase 3	Non-Small Cell Lung Cancer	2022-11-01	12.5
A Study of Potential Disease Moc	Phase 2/Phase 3	Dementia	2022-11-30	11.3
A Study of Potential Disease Moc	Phase 2/Phase 3	Alzheimers Disease	2022-11-30	11.3
A Study of Potential Disease Moc	Phase 2/Phase 3	Alzheimers Disease, Familial	2022-11-30	11.3
PD-1 Inhibitor Combined With Ne	Phase 3	Oesophageal Cancer	2022-11-01	8.3
PD-1 Inhibitor Combined With Ne	Phase 3	Esophageal Cancer	2022-11-01	8.3
PD-1 Inhibitor Combined With Ne	Phase 3	Squamous Cell Esophageal Carcinoma	2022-11-01	8.3
Total Neoadjuvant Therapy of SC	Phase 3	Locally Advanced Rectal Cancer	2022-11-21	8.1
Regorafenib With Low-dose Cher	Phase 2/Phase 3	Metastatic Colorectal Cancer	2022-11-30	8
Intravesical BCG vs GEMDOCE i	Phase 3	Non-muscle-invasive Bladder Cancer	2022-11-30	7.9
A Study of Dato-DXd With or With	Phase 3	Breast Cancer	2022-11-30	7.3
Neoadjuvant Therapy of Sintilima	Phase 3	Squamous Cell Non-small Cell Lung Cancer	2022-11-11	7
Adjuvant Trial in Patients With Re	Phase 3	Pancreatic Ductal Adenocarcinoma	2022-11-01	6.8
Mirvetuximab Soravtansine With	Phase 3	Peritoneal Cancer	2022-11-30	6.4

**Figure 1: Significant Indications by Average Expected Durations
(Initiated between 11/01/2022-11/30/2022)**



Our database shows that the average duration is longest for clinical trials in treating Spinal Muscular Atrophy (SMA), and it is expected to last over 16 years. On the top of this list, Non-Small Cell Lung Cancer and Dementia are also expected to undergo a very long clinical trials (exceeding 11 years), respectively.

If you would like to know more comprehensive lists of indications and clinical trials, please contact us at contact@buttontech.us.

2 Significant Clinical Trials by Enrollment


Generally speaking, a clinical trial with more enrollments may bring more business opportunities to other companies, such as CROs.

Table 2 shows **the enrollments of clinical trials** initiated between November 1st and 30th 2022, ranked in descending order. Figure 2 shows **the total enrollments by indications** for these clinical trials, ranked in descending order.

**Table 2: Significant Clinical Trials by Enrollments
(Initiated between 11/01/2022-11/30/2022)**

Title	Phase	Indication	Enrollment
Recommendations of Enhanced Recovery Interventions for F	Phase 3	Perioperative Optimization	35,485
Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Pt	Phase 3	Coronavirus Infections	16,000
Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Pt	Phase 3	COVID-19	16,000
COLchicine and Non-enteric Coated Aspirin in the Cardiovas	Phase 3	Cardiovascular Diseases	10,000
COLchicine and Non-enteric Coated Aspirin in the Cardiovas	Phase 3	Diabete Type 2	10,000
A Phase III Study to Evaluate the Efficacy, Immunogenicity, S	Phase 3	AIS	10,000
A Phase III Study to Evaluate the Efficacy, Immunogenicity, S	Phase 3	CIN2	10,000
A Phase III Study to Evaluate the Efficacy, Immunogenicity, S	Phase 3	CIN3	10,000
A Phase III Study to Evaluate the Efficacy, Immunogenicity, S	Phase 3	Vain I	10,000
A Phase III Study to Evaluate the Efficacy, Immunogenicity, S	Phase 3	CIN1	10,000
A Phase III Study to Evaluate the Efficacy, Immunogenicity, S	Phase 3	Vain III	10,000
A Phase III Study to Evaluate the Efficacy, Immunogenicity, S	Phase 3	Genital Wart	10,000
A Phase III Study to Evaluate the Efficacy, Immunogenicity, S	Phase 3	Cervical Cancer	10,000
A Phase III Study to Evaluate the Efficacy, Immunogenicity, S	Phase 3	VAIN - Vaginal Intraepithelial Nec	10,000
A Phase III Study to Evaluate the Efficacy, Immunogenicity, S	Phase 3	Vin III	10,000

**Figure 2: Significant Indications by Total Enrollments
(Initiated between 11/01/2022-11/30/2022)**



If we check out the correlation between clinical trial's enrollment number and indication, we can find out that the number of total enrollments, compared to the previous two months (September, October), has increased sharply – although consistent observations are needed, this could be a sign and a proof showing that many economic/business activities are going back to normal modes.



3 Contact Us for Customized Business Intelligence Analysis

Please contact us at contact@buttontech.us if you are interested in getting to know about latest clinical trials in more details, such as:

- **Active PIs;**
- **Active sponsors;**
- **Latest clinical trials for particular enrollment sizes, durations, indications, and eligibility criteria;**
- **Leading clinical experts in a particular field/area;**
- **Other customized business intelligence analysis for clinical trials.**

Powered by BUTTON Platform

2672 Bayshore Parkway, Suite 1001, Mountain View, CA 94043

WEB: <https://www.button-corp.com> EMAIL: contact@buttontech.us